Previous 10 | Next 10 |
Avadel's FT218 is claimed to be a better version of Xyrem. Xyrem, or rather sodium oxybate, is a multibillion-dollar market. Key competition now is, however, Xywav. For further details see: Avadel's Xyrem Competitor: A Quick Overview
DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, ...
DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced ...
DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced ...
Image source: The Motley Fool. Avadel Pharmaceuticals plc (NASDAQ: AVDL) Q3 2020 Earnings Call Nov 9, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Avadel Pharmaceuticals plc (AVDL) Q3 2020 Earnings Call Transcrip...
Avadel Pharmaceuticals plc (AVDL) Q3 2020 Earnings Conference Call November 09, 2020, 08:30 AM ET Company Participants Thomas McHugh - CFO Greg Divis - CEO Conference Call Participants David Amsellem - Piper Sandler Paul Matteis - Stifel Francois Brisebois - Oppenheimer Matt Kaplan - Ladenbur...
Avadel Pharmaceuticals plc (AVDL) Q3 2020 Earnings Conference Call November 9, 2020 8:20 A.M. ET Company Participants Thomas McHugh - Chief Financial Officer Greg Divis - Chief Executive Officer Conference Call Participants David Amsellem - Piper Jaffray Paul Matthews - Stifel Oren Livnat - H...
Avadel Pharmaceuticals (AVDL): Q3 GAAP EPS of -$0.20 beats by $0.04.Cash, cash equivalents and marketable securities of $231.6MPress Release For further details see: Avadel Pharmaceuticals EPS beats by $0.04
NDA for once-nightly FT218 is on track for FDA submission by end of December 2020 New market assessment data identifies a significant potential marke t expansion opportunity for once-nightly FT218 be...
DUBLIN, Ireland, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, annou...
News, Short Squeeze, Breakout and More Instantly...
Avadel Pharmaceuticals plc Company Name:
AVDL Stock Symbol:
NASDAQ Market:
Avadel Pharmaceuticals plc Website:
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Ind...
2024-05-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -...